Find out more
DiMedical Clinical Medicine Center is an innovative biomedical company operating in the field of clinical medicine, laboratory diagnostics, research and development (R&D), using modern medical technologies. The company was established in 2016 in Lodz, and its main goal is to develop and implement unique diagnostic methods in the field of infectious and cancerous diseases.Find out more
DiMedical Clinical Medicine Center was awarded the Polish Intelligent Development Award in the category of 'Medicine and pharmacy of the future' in 2018.
We are extremely pleased that our company has once again been appreciated by the Congress Council of the Polish Congress of Entrepreneurship. We received the Fundament 2021 award for pro-social activities, strongly contributing to the development of diagnostics towards the detection of SARS-CoV-2 virus.
DiMedical Clinical Medicine Center has implemented the terms of the SARS-CoV-2 INTERNATIONAL EXTERNAL QUALITY CONTROL PROGRAM (EQA). The diagnostic method verified was the reverse-transc.ription polymeraze chain reaction (RT-PCR). The certificate is valid from 07/25/2021 to 07/25/2022.
We are pleased to announce that DiMedical was nominated for the title of "Polish Innovation Award 2019" in the medicine category, for the implementation of a project related to the implementation of an innovative method of diagnosing tuberculosis and other mycobacteriosis.
The DiMedical Clinical Medicine Center participated in the QCMD 2021 SARS-CoV-2 EQA Program. Thus, confirming the credibility of the diagnostic activities performed as part of the detection of the SARS-CoV-2 genome. The certificate is valid from 07/19/2021 - 07/19/2022.
The MADE IN POLAND Congress aims to highlight the potential of Polish producers who have a significant impact on the shape and development of the Polish economy in various industries.
DiMedical Clinical Medicine Center has implemented the terms of the SARS-CoV-2 INTERNATIONAL EXTERNAL QUALITY CONTROL PROGRAM (EQA). The diagnostic method verified was the immunochromatographic test. The certificate is valid from December 26, 2021 to December 26, 2022.
Our company was the laureate of the foundation 2020 award. The project concerning the rapid diagnosis of tuberculosis played an important role in the award. We treat this award as a kind of confirmation that the direction of work we have chosen is good and noticeable in the medical community.
Our laboratory met the conditions of the POLMICRO/SSE program. This confirms the high quality of the microbiological diagnostics performed by the center.
DiMedical Clinical Medicine Center has implemented the terms of the SARS-CoV-2 INTERNATIONAL EXTERNAL QUALITY CONTROL PROGRAM (EQA). The diagnostic method verified was the reverse-transcription polymeraze chain reaction (RT-PCR). The certificate is valid from 07/24/2022 to 07/24/2023.
DiMedical, in addition to research and development, specializes in commercial clinical and laboratory diagnostics, including the diagnosis of SARS-CoV-2 virus infections.
The company provides services in the field of medical laboratory diagnostics, based on techniques of mass spectrometry, molecular biology, genetics and microbiology.Find out more about our R&D